Evidence mapPaperPMID 41565312Full record

SynthesisBMJ open ophthalmology2026

Retinal biomarkers for early Alzheimer's detection: a systematic review of optical coherence tomography (OCT) findings.

Maryne Lepoittevin, Jenny Greig, Ozlem Erol, Alaedine Benani, Pierre Bauvin, Claudio Azzolini, Simone Donati, Bruno Dubois, Claude Boscher, Sylvain Bodard

Abstract readSystematic Review
In one paragraph

Synthesis in BMJ open ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. AI-driven multimodal retinal imaging for early detection and risk stratification of vascular and neurodegenerative diseases.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maryne LepoittevinPreventive Medicine, Data Science and AI Lab, Zoī SAS, Paris, France maryne.lepoittevin@zoi.com.ORCID http://orcid.org/0009-0001-4159-244X
Jenny GreigPreventive Medicine, Data Science and AI Lab, Zoī SAS, Paris, France.
Ozlem ErolPreventive Medicine, Data Science and AI Lab, Zoī SAS, Paris, France.
Alaedine BenaniPreventive Medicine, Data Science and AI Lab, Zoī SAS, Paris, France.
Pierre BauvinPreventive Medicine, Data Science and AI Lab, Zoī SAS, Paris, France.
Claudio AzzoliniAdvisory Council for e-Health/Telemedicine, Scientific Director of TM95 Ltd, Milano, Italy, University of Insubria, Varese - Como, Italy.
Simone DonatiDepartment of Medicine and Surgery, University of Insubria, Varese - Como, Italy.
Bruno DuboisCentre MEG-EEG, CENIR, Institut du Cerveau-Paris Brain Institute (ICM), INSERM U 1127, CNRS UMR 7225, AP-HP, Hôpital de La Pitié-Salpêtrière, Sorbonne Université, Paris, France.
Claude BoscherFondazione Retina 3000, Milan, Italy.
Sylvain BodardService d'Imagerie Adulte, AP-HP, Hôpital Universitaire Necker-Enfants Malades, Université Paris Cité, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRetinal biomarkers accessible via non-invasive optical coherence tomography (OCT) could facilitate early detection of Alzheimer's disease (AD), complementing current invasive or costly diagnostic methods. This review evaluates the evidence for spectral-domain OCT (SD-OCT) and OCT angiography (OCT-A) in identifying retinal changes associated with preclinical and early AD. METHODS AND ANALYSIS: We conducted a systematic review registered in PROSPERO and aligned with Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. PubMed/MEDLINE was searched up to April 2025, complemented by reference list screening and citation tracking. Eligible studies assessed SD-OCT and/or OCT-A in biomarker-defined preclinical or early AD, mild cognitive impairment or mild AD. Data were synthesised narratively by disease stage, and methodological quality was appraised with the Newcastle-Ottawa Scale.

results22 studies met inclusion criteria. Reported alterations included thinning of the peripapillary retinal nerve fibre layer and retinal ganglion cell layer, macular and choroidal thickness changes and microvascular alterations on OCT-A. However, findings were heterogeneous: some studies observed early thickening or increased vascular density, possibly reflecting inflammatory or compensatory mechanisms, while others reported thinning and rarefaction more consistent with neurodegeneration. Most studies were of moderate quality, limited by small sample sizes, cross-sectional designs and incomplete control for ocular/systemic confounders.

conclusionSD-OCT and OCT-A hold promise as candidate biomarkers of early AD, but current evidence remains variable, non-specific and methodologically constrained. Further research is needed to standardise imaging protocols, validate findings in biomarker-confirmed longitudinal cohorts and compare OCT-based measures across dementia subtypes. Integration with other biomarkers (eg, plasma or metabolomics) may improve diagnostic specificity and support translation of OCT/OCT-A into clinical practice. PROSPERO REGISTRATION NUMBER: CRD42024600456.

Indexed as

Alzheimer DiseaseBiomarkersRetinaTomography, Optical CoherenceEarly DiagnosisHumansRetinal Ganglion CellsBiomarkersDegenerationImagingRetina

Identifiers

PMID41565312
PMCPMC12829385

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.